-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
U.S. regulators have approved Roche's new Full Tumor Liquid Biopsy Test Platform (FoundationOne Liquid CDx) for patients with solid tumors, which will provide an alternative for patients who are unable to perform an tissue biopsy.
FoundationOne Liquid CDx is a Genomic Analysis (CGP) test that analyzes more than 300 cancer-related genes and multiple genomic characteristics to identify genetic mutations in tumors and optimize patient care.
One Liquid CDx was able to analyze cellless DNA circulating in a patient's blood sample and use large-scale parallel sequencing to detect four major genomic changes.
regulator also approved the test to identify patients who may benefit from certain prostate and lung cancer treatments, including Rucaparib and three first-line tyrosine kinase (TKI) inhibitors.
cancer patients are unable to perform tissue biopsies," said Levi Garraway, chief medical officer and executive vice president of Roche.
One Liquid CDx may offer minimally invascopic treatment options for patients who might not otherwise benefit from comprehensive genomic analysis.
the convenience of testing blood samples can also make treatment decisions faster, so that patients can rest assured that time is wasted and time is buyable for efficient treatment."
.